Navigation Links
PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel
Date:7/10/2008

ANNAPOLIS, Md., July 10 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that Jordan P. Karp, J.D., has been appointed Senior Vice President & General Counsel, overseeing all legal and human resources matters for PharmAthene.

Mr. Karp joins PharmAthene with over 17 years of legal experience in a variety of areas, including SEC compliance, corporate governance, mergers and acquisitions, government and commercial contracting, and intellectual property.

Prior to joining the Company, Mr. Karp was employed by Constellation Energy Group, Inc., a diversified Fortune 125 energy company, from 2001 to 2007. From October 2002 to November 2007, Mr. Karp served as Vice President & General Counsel for one of Constellation Energy's primary operating divisions, Constellation NewEnergy, Inc., a leading retail marketer of electricity and natural gas. Mr. Karp established and managed the legal function for Constellation NewEnergy during a period of rapid growth, in which annual revenues for Constellation's retail energy marketing segment increased from $2.6 billion in 2003 to $9.1 billion in 2007.

Before his tenure at Constellation, Mr. Karp held in-house legal positions of increasing responsibility at MCI Communications Corp., Guilford Pharmaceuticals Inc., and Mentor Technologies Group, Inc., where Mr. Karp served as Vice President, General Counsel & Corporate Secretary. Following a one year judicial clerkship on the U.S. Third Circuit Court of Appeals, Mr. Karp started his legal career as an associate attorney with the international law firm, Hogan & Hartson LLP, focusing
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PharmAthene Reports First Quarter 2008 Financial Results
2. PharmAthene to Host First Quarter 2008 Conference Call and Webcast on Tuesday, May 13, 2008
3. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
4. PharmAthene Reports Year-End 2007 Financial Results
5. Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthenes Protexia(R) Program
6. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
7. PharmAthene to Delay Release of Full Year 2007 Financial Results
8. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
9. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
10. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
11. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
Post Your Comments:
*Name:
*Comment:
*Email: